Sugi Predict

Sugi Predict / Compounds / SCHEMBL2446579

SCHEMBL2446579

SCHEMBL2446579

COC(=O)[C@H](CCI)NC(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 11/20 0.44
▸ CTSS P25774 7/20 0.44
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ CA7 P43166 1/20 0.42
▸ CTSL P07711 2/20 0.41
▸ CTSB P07858 1/20 0.41
▸ NFKB1 P19838 1/20 0.41
▸ NFKB2 Q00653 1/20 0.41
▸ RELA Q04206 1/20 0.41
▸ KLK5 Q9Y337 1/20 0.41
▸ CA12 O43570 1/20 0.40
▸ CA14 Q9ULX7 1/20 0.40
▸ CYP2D6 P10635 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1338105 1.00 CTSK (0.44) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL13640201 1.00 CTSK (0.44) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL29727325 0.92 CTSK (0.50) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL30788958 0.92 CTSK (0.46) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL4702036 0.87 CYP1A2 (0.58) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL1519852 0.86 CYP1A2 (0.46) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL1712024 0.86 CYP1A2 (0.46) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL1743738 0.86 CYP1A2 (0.46) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL24299005 0.85 CTSK (0.46) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL22035781 0.85 CTSK (0.46) CTSKCTSSCYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015313-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF PEPTIDREAM INC (JP) 2026-01-15 — — US disclosed
US-12371434-B2 MLL1 inhibitors and anti-cancer agents CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) 2025-07-29 — — US disclosed
EP-4534524-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF PeptiDream Inc. (JP) 2025-04-09 — — EP disclosed
CN-114929705-B MLL1 inhibitors and anticancer agents 诺华公司 2024-09-13 — — CN disclosed
EP-4013754-B1 MLL1 INHIBITORS AND ANTI-CANCER AGENTS NOVARTIS AG (CH) 2024-07-24 — — EP disclosed
WO-2023234425-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF ペプチドリーム株式会社 2023-12-07 — — WO disclosed
CN-114929705-A MLL1 inhibitor and anticancer agent 诺华公司 2022-08-19 — — CN disclosed
EP-4013754-A1 MLL1 INHIBITORS AND ANTI-CANCER AGENTS Novartis AG (CH) 2022-06-22 — — EP disclosed
US-10793604-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2020-10-06 — — US disclosed
US-10647744-B2 Tripeptide epoxy ketone protease inhibitors ONYX THERAPEUTICS, INC. (US) 2020-05-12 — — US disclosed
EP-1997809-A2 Indazole, benzoxazole and pyrazolopyridine derivatives for medical use Array Biopharma Inc. (US) 2008-12-03 — — EP disclosed
EP-1606283-B1 P38 INHIBITORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC (US) 2008-10-08 — — EP disclosed
WO-2004078116-A9 P38 INHIBITORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC (US) 2008-09-12 — — WO disclosed
US-7378079-B2 Agents for imaging and diagnostic methods using them NST NEUROSURVIVAL TECHNOLOGIES LTD. (IL) 2008-05-27 — — US disclosed
US-20070208180-A1 Process for Preparation of Nonnatural Amino Acid and Intermediate Thereof DAISO CO., LTD. (JP) 2007-09-06 — — US disclosed
EP-1606283-A4 P38 INHIBITORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC (US) 2007-05-23 — — EP disclosed
EP-1739077-A1 PROCESS FOR PRODUCTION OF NONNATURAL AMINO ACIDS AND INTERMEDIATES THEREFOR DAISO CO., LTD. (JP) 2007-01-03 — — EP disclosed
EP-1606283-A2 P38 INHIBITORS AND METHODS OF USE THEREOF Array Biopharma, Inc. (US) 2005-12-21 — — EP disclosed
US-20040192653-A1 P38 inhibitors and methods of use thereof ARRAY BIOPHARMA INC. 2004-09-30 — — US disclosed
WO-2004078116-A2 P38 INHIBITORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA, INC. (US) 2004-09-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12371434-B2 MLL1 inhibitors and anti-cancer agents MLLT1, BMI1, DOT1L CTSK 4303/4885CTSS 4653/4885CYP1A2 4047/4885
US-20070208180-A1 Process for Preparation of Nonnatural Amino Acid and Intermediate Thereof BCAT1, BCAT2, AADAT CTSK 3187/4885CTSS 2807/4885CYP1A2 189/4885
US-20260015313-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF NSUN3, BCAT1, SLC43A1 CTSK 4661/4885CTSS 4022/4885CYP1A2 2870/4885
US-10793604-B2 Anthelmintic depsipeptide compounds VIP, PREP, DNPEP CTSK 204/4885CTSS 245/4885CYP1A2 1102/4885
US-10647744-B2 Tripeptide epoxy ketone protease inhibitors PREP, CTRL, ENPEP CTSK 48/4885CTSS 137/4885CYP1A2 1156/4885
US-20040192653-A1 P38 inhibitors and methods of use thereof MAPK1, MAPK3, MAPK8 CTSK 2205/4885CTSS 3593/4885CYP1A2 2617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.